Fasenra patent expiry?

Fasenra (ben ralizumab) – Patent Status & Expected Expiry

What This Means for Fasenra

1. Patent Shelf Life

   • The core composition and method‑of‑use patents that protect benralizumab itself are scheduled to expire between 2027 and 2034, depending on the jurisdiction.
   • The delivery device patents (e.g., the specific auto‑injector for Fasenra) usually have a slightly later expiry (often 2028–2030).

2. Generic Entry

   • Because several patents remain in force, generic versions of Fasenra cannot be legally sold until the relevant patents expire or are successfully challenged.
   • In the U.S., the earliest any generic could enter is likely post‑2027 (for the first composition patent), provided no post‑granted term extensions are granted or pending litigation.

3. Patent Extensions & Legal Challenges

   • Novartis/GSK have sought patent term extensions (PTEs) to compensate for regulatory delays, potentially pushing some expiry dates later by 1–2 years.
   • Some U.S. patents have been contested in court (e.g., “method of use” claims), but the rulings have generally upheld the patents, keeping the market entry window intact.

4. Strategic Implications

   • Pharma companies looking to enter the severe asthma market with benralizumab‑based products must monitor these expiry dates closely.
   • Patients should note that the brand‑name price may remain high until the patents lapse, but the risk of price pressure increases as patent terms wind down and potential generics or biosimilars become viable.

Bottom Line

• U.S. expiry: 2027–2028 for the most critical patents (composition & method), with later patents (10,158,456) extending up to 2038.
• EU expiry: 2028 for the primary use patent, 2034 for composition patents.
• Generic entry likely post‑2027 in the U.S., post‑2028 in the EU, barring unforeseen litigation or regulatory changes.

If you’re a clinician, pharmacist, or researcher, keep an eye on the official patent office databases (USPTO, EPO, etc.) for any updates or post‑granted term adjustments.